Biotech investors are preparing for what may be the most important clinical trial readout for them this summer.

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

The consistent outperformance in multiple forms of administration against multiple existing standards of care is certainly very bullish for Summit, whose stock is nearly all the way back to an ...

We recently published a list of These 10 Firms Soared Last Week, Here’s Why. In this article, we are going to take a look at ...

Summit Therapeutics PLC (SMMT) closed the last trading session at $28.02, gaining 61.8% over the past four weeks, but there ...

Keytruda is set to lose exclusivity in 2028, meaning Summit may face competition from cheaper biosimilars. Meanwhile, other ...

Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced the grant of inducement awards of ...

In this article, we are going to take a look at where Summit Therapeutics Inc. (NASDAQ:SMMT) stands against other best cancer stocks to invest in for long-term gain. After cardiovascular disease ...

Summit Therapeutics (NASDAQ: SMMT) has more than just a potential blockbuster cancer drug in its portfolio. Ivonescimab could be one of the best drugs to ever hit the market. This has investors ...